Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239

Veru Inc. (VERU) reported fiscal 2026 Q3 results ended June 30, 2026, with a net loss of $7.0 million, or $0.30 per share. The Phase 2b PLATEAU trial of enobosarm plus semaglutide is fully enrolled with 239 patients. Interim analysis is expected in Q1 2027, final topline in Q4 2027. Cash was $23.9 million.

Original reporting
Published Aug 10, 2026, 11:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 11:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239 — source image
Decision brief

The 30-second read

$VERUNeutralMed
01

Why it matters

The new information is the combination of (1) fiscal Q3 loss and expense trends, (2) PLATEAU fully enrolled at 239 patients, and (3) timing for interim and final topline data plus a USPTO notice of allowance for a key US patent.

02

Market read

Traders can reassess trial execution progress versus ongoing burn, using the updated enrollment count and the stated interim and final topline windows.

03

What to watch

Cash is $23.9M as of June 30, 2026, and R&D and operating losses remain substantial, which could dominate valuation even with trial progress and patent allowance.

Relevance 7/10Novelty 7/10Timing: reported pre-market/late morning Aug. 10, 2026

Background

Veru is advancing a Phase 2b PLATEAU trial using enobosarm plus semaglutide for high quality weight loss, with interim analysis targeted for early calendar 2027.

Company-level read

Ticker impact

$VERUNeutralMedium confidence
Context

Veru reported fiscal Q3 net loss of $7.0M and said its PLATEAU Phase 2b trial is fully enrolled with 239 patients.

Expected impact

Near-term sentiment likely modestly positive on enrollment progress, offset by continued losses and limited cash runway.

Evidence & confidence

The article provides concrete trial status (fully enrolled) and a timeline for interim and final topline data, but it does not include revenue upside or a balance-sheet improvement beyond the stated cash figure.

Market effects

Adds another datapoint for obesity/weight-loss drug development timelines and the competitive importance of trial enrollment and IP protection.

No clear regional spillover beyond US biotech sentiment.

Novo Nordisk supply agreement mention may reinforce global supply-chain and collaboration expectations in GLP-1-adjacent development.

Counterpoint

Fully enrolled does not guarantee efficacy; interim results being “on track” is not the same as positive clinical signals, so the stock may still trade primarily on cash burn and future topline risk.

Key entities

  • Veru Inc.

    Reported fiscal 2026 Q3 net loss and provided an update that PLATEAU is fully enrolled with 239 patients, with interim analysis on track for Q1 2027.

  • PLATEAU

    Phase 2b trial of enobosarm and semaglutide for high quality weight loss; enrollment completed at 239 patients.

  • Novo Nordisk

    Cited a June 2026 clinical supply agreement related to the trial.

  • USPTO

    Issued an August 2026 notice of allowance for a key US patent expected to protect until at least October 2044.

Related articles

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$VERUMedAI 8/10

Veru executive to present obesity drug data at industry conference

Veru Inc. (VERU) will present obesity drug data at ObesityWeek 2026. Dr. Gary Barnette will discuss physical function in older patients using a GLP-1 receptor agonist from the QUALITY study. The company's Phase 2b PLATEAU trial has enrolled 239 patients, exceeding targets. Interim results are expected in Q1 2027, with final data in Q4 2027, according to the company.

$VERUMed

Why is Veru stock gaining today?

Veru Inc. (VERU) shares rose 1.8% after Oppenheimer reiterated its Outperform rating and $24 price target, citing confidence in enobosarm's Phase 2b trial results. The trial, fully enrolled with 239 patients, aims to show lean body mass preservation and fat loss benefits. Veru holds a U.S. patent for the enobosarm-semaglutide combination until 2044. The stock traded at $2.23, below its 52-week high of $7.33 but above its low of $2.05.

$VERUHighAI 8/10

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™)…

VERU INC. (VERU) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib

$VERUMed

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

VERU INC. (VERU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress — Phase 2b PLATEAU cl